Trial Profile

A prospective cohort study of immunogenicity and reactogenicity US Food and Drug Administration Emergency Use Authorization vaccines in a large cohort of patients: Cancer, COVID, and Vaccination (CANVAX) study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 16 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Dec 2021 Results from this and other studies comparing the immunogenicity of mRNA-1273, BNT-162b2 or Ad26.COV2.S in healthy ambulatory adults, published in the Journal of Infectious Diseases
15 Nov 2021 New trial record
09 Nov 2021 Primary endpoint (neutralization titers) has been met, according to Results published in the Journal of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com